On May 26 (today), Eli Lilly announced agreements to acquire three vaccine companies — Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. — officially entering the human vaccine arena.

This acquisition is part of Eli Lilly's strategy to continuously invest in differentiated technology platforms and tackle major health challenges. In its 150-year history, Lilly has made significant progress in diabetes, obesity, Alzheimer's disease, autoimmune diseases, and cancer. Infectious diseases, as a major driver of global morbidity, still pose unresolved public health challenges in terms of acute illness and long-term health consequences from primary infections.

Dr. Daniel M. Skovronsky, Eli Lilly's Chief Scientific and Product Officer and President of Lilly Research Laboratories, stated that this acquisition reflects the company's strategic direction of preventing disease at its source rather than merely treating its consequences. Existing research shows that common infections may trigger neurological diseases, cancer, infertility, and other conditions years later. Meanwhile, growing antibiotic resistance is limiting treatment options for bacterial infections, making vaccines an increasingly important preventive approach. The combination of the three companies' technology platforms and R&D teams with Lilly's global industrial scale is expected to improve this disease trajectory.

Eli Lilly is writing acquisition checks with increasing speed. This deal signals that differentiated preventive assets are becoming an important choice for big pharma to combat the patent cliff and fill pipeline gaps.
Core Assets and Deal Terms of the Three Acquired Companies:

Curevo's lead candidate is amezosvatein, an adjuvanted subunit vaccine for the prevention of herpes zoster (shingles) in adults.

Although current mainstream shingles vaccines are effective, poor tolerability has led to low overall vaccination rates, with some populations hesitant about the second dose, leaving many patients without adequate protection and at risk of long-term disease complications. Amezosvatein incorporates a next-generation synthetic adjuvant developed to address this issue. In a Phase 2 head-to-head trial, the vaccine achieved immune responses comparable to the standard of care across all primary efficacy endpoints, while significantly reducing — by more than half — adverse events affecting daily activities, including fatigue, chills, and injection site pain.

Existing research confirms that shingles increases the risk of stroke, and shingles vaccination has been associated with a reduced risk of dementia. A vaccine with substantially improved tolerability could expand the coverage of shingles prevention, reducing associated long-term disease risks at the population level.

Deal Terms: Eli Lilly will acquire Curevo for $1.5 billion in cash, including an upfront payment and subsequent milestone payments upon achievement of specified milestones.

LimmaTech Biologics focuses on vaccine development against drug-resistant pathogens.

As antimicrobial resistance escalates year by year, treatment options for bacterial infections such as Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis continue to shrink. The company has a proprietary technology platform that targets bacterial toxins and superantigens, inducing broad and durable immune responses to tackle complex bacterial targets.

Its core pipeline candidate, LTB-SA7, is in Phase 1 clinical development for the prevention of Staphylococcus aureus infections — the leading cause of surgical site infections. The preclinical pipeline also covers multiple other pathogens, particularly those that can cause infertility and long-term post-infection complications in women. A vaccine-centered prevention approach holds promise for improving the disease course of these difficult-to-treat infections.

Deal Terms: Eli Lilly will acquire LimmaTech for up to $780 million in cash, including an upfront payment and additional payments upon achievement of clinical and regulatory milestones.

Vaccine Company has developed a proprietary In Vivo Nanoparticle (IVN) technology that achieves the antigen presentation characteristic of virus-like particle (VLP) vaccines, inducing long-lasting immune responses while avoiding the complex manufacturing processes and high costs associated with traditional VLP vaccines. The company's preclinical pipeline includes multiple viral vaccines covering various pathogens.

Its lead candidate is a five-antigen Epstein-Barr Virus (EBV) vaccine developed using this technology, which is ready for Phase 1 clinical filing. Extensive research has confirmed that EBV is closely associated with multiple sclerosis and various malignancies. This preventive vaccine could not only prevent acute infectious mononucleosis but also reduce the long-term risk of neurological diseases and tumors following infection.

Deal Terms: Eli Lilly will acquire Vaccine Company for up to $1.55 billion in cash, including an upfront payment and milestone payments upon achievement of clinical and commercialization milestones.

Looking at pipeline stage, all of the core products acquired by Eli Lilly in this deal are in early clinical or preclinical stages, meaning there is still a long road ahead before commercialization and meaningful revenue generation.

Notably, Eli Lilly is no newcomer to the vaccine field. Although it had no active human vaccine pipeline prior to this acquisition, the company has a deep vaccine heritage. For example, during World War II, Lilly produced vaccines for encephalitis, typhus, influenza, and gas gangrene antitoxin. In 1955, it became the world's first company to mass-produce and commercialize the Salk polio vaccine, supplying 60% of the U.S. market that year.

Eli Lilly's heavy investment in returning to the vaccine arena may represent an ambition to complete a full-chain disease management model — from treatment to prevention.

Although early-stage pipelines generally carry risks of uncertain clinical success and long development timelines, Lilly's global clinical development capabilities and established commercial network will provide unique advantages in advancing these assets.

Currently, nearly 90% of the global vaccine market is still controlled by four major players: Pfizer, GSK, Merck, and Sanofi. In recent years, due to policy changes and market saturation in certain segments, these leading companies are seeking transformation amid declining performance — yet Eli Lilly has chosen this moment to double down.
This acquisition reflects a broader trend in the global biopharmaceutical industry — shifting from "treating established disease" toward "blocking disease at its source." Vaccines remain the best means of disease prevention.